Overall, based on the lipid profile results and metabolic analysis supported by molecular analysis, both carboxamide derivatives showed promising lipid-lowering activity and displayed regulatory activity of metabolic pathways that were disturbed by hyperlipidemia induction. The efficacy of carboxamide compounds was comparable to the conventional lipid-lowering drug, fenofibrate. Compound A exhibited superior activity significantly lowering triglycerides levels and restoring many of the metabolic alterations induced in hyperlipidemia.
Alwahsh et al. (Thu,) studied this question.